Navigation Links
Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
Date:12/14/2007

Effectiveness Of ARIMIDEX Still Evident More Than Three Years After

Treatment

SAN ANTONIO, Texas, Dec. 14 /PRNewswire-FirstCall/ -- Data released today show a continued benefit of ARIMIDEX when compared to tamoxifen in treating postmenopausal women with hormone receptor-positive (HR+) early breast cancer. Results of the ATAC (ARIMIDEX, Tamoxifen, Alone or in Combination) trial, reported today at the 2007 San Antonio Breast Cancer Symposium, represent a median follow-up of more than eight years and show an absolute reduction in the risk of recurrence and distant recurrence with ARIMIDEX. The ATAC trial is one of the world's longest and largest breast cancer studies and is supported by AstraZeneca.

With approximately 2.5 million breast cancer survivors in the United States today, the ATAC 100-month analysis marks a major milestone in understanding the treatment of HR+ early breast cancer(1). The data show that the effects of ARIMIDEX in decreasing the risk of recurrence compared with tamoxifen continue even after patients have completed therapy.

At a median follow-up of 100 months, more than three years after the completion of treatment, ARIMIDEX significantly reduces the risk of recurrence in comparison with tamoxifen in postmenopausal patients with HR+ breast cancer. A significant benefit of ARIMIDEX on distant recurrence is now evident (HR+population p=0.027), and ARIMIDEX is also shown to reduce the risk of distant metastases. Although there was no difference in overall survival, the impact of ARIMIDEX at reducing distant metastases is important, as distant recurrence-free survival is an important predictor for survival related to breast cancer(2).

"The long-term data from the ATAC trial continue to impact the way physicians worldwide treat postmenopausal women with hormone receptor-positive early breast cancer," said Aman U. Buzdar, MD, who represents North America on the ATAC Steering Committe
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
2. Battle Continues Over Vietnam PTSD Numbers
3. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
4. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
5. Securians Minnesota Life Continues to Climb Group Life Rankings
6. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
7. United States continues to have highest level of health spending
8. LehmanMillet Continues Expansion with Strategic Hires
9. American Cancer Society report finds breast cancer death rate continues to drop
10. CIGNA HealthCare Continues Gains in Health Care Quality
11. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... New Energy Works Timberframers invites the public to join their timber frame ... 9am – 12pm. Timber frame raisings are special, celebrating both craft and ... culmination of months of effort, planning, fundraising, and dreaming takes shape. , “There’s ...
(Date:7/31/2015)... ... 31, 2015 , ... Super-Sod wants to participate in planning new home lawns ... as the perfect fit for such a goal. Houzz is a social media site ... a dynamic site that spreads home and home garden design ideas when members share ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec ... the recent implementation of Microsoft Dynamics GP for a senior living facility in ... now supporting senior living communities in 16 states. This further expansion was again ...
(Date:7/30/2015)... ... , ... Dale Sky Jones, Executive Chancellor of Oaksterdam University , the ... Expo held at the Caribe Royal All Suites Hotel and Convention Center in Orlando, ... the largest medical cannabis expo in the country and this year’s expo will be ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, ... an app invention that can help people during emergencies. , "The worldwide mobile ... and Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile ...
Breaking Medicine News(10 mins):Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5
... Mich. Scientists at Michigan State University have found ... inflammation in the mammary gland. This progesterone-induced ... risk of breast cancer. Progesterone is a naturally ... mammary gland. Progesterone previously has been identified as a ...
... the University of Pittsburgh School of Medicine have shown that ... is required for their biological activity. This shape-changing also allows ... to select the structure that permits the best binding. That ... that will have the most impact on protein function to ...
... , ORLANDO, Fla., Aug. 19 Valensa ... has dramatically increased the stability and shelf-life of the ... a 7-year shelf-life study of its Zanthin(R) natural astaxanthin ... of Haematococcus pluvialis, bolstered by Valensa,s proprietary O2B(R) Peroxidation ...
... , ... over 1,000 physicians across America regarding after-hours call management, human operator error was cited as ... frustration in their medical practice. , ... Knoxville, Tenn. (PRWEB) Aug. 19, 2009 -- In a survey of over 1,000 ...
... Programs Open Doors to Highlight Their Advanced Care Regimens ... of National Senior Citizens Day, this Friday, August 21(st), the National ... All-inclusive Care for the Elderly (PACE) around the country to educate ... Designed to serve individuals over 55 and in need of ...
... Maine, Aug. 19 Anthem Blue Cross and Blue Shield ... the administration of the H1N1 (swine flu) vaccine when it ... will be covered for members whose benefit plans provide coverage ... continue coverage of seasonal flu vaccine administration for those whose ...
Cached Medicine News:Health News:MSU scientists: Progesterone leads to inflammation 2Health News:Pitt scientists find intrinsic changes in protein shape influence drug binding 2Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 2Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 3Health News:Physicians Citing Human Error as Top Communication Problem 2Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 2Health News:National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 3Health News:Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration 2
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... 2015 Takeda Pharmaceutical Company Limited ("Takeda") ... the post-marketing commitment and submissions of data to ... Bladder Cancer Risk Characterization Study , a large ... in four European countries, for pioglitazone containing medicines, ... years of follow-up. Findings demonstrate that there is ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Reportlinker.com announces that a new market ... , Analysis of the Material ... 2009 was one of ... economy, the material test equipment market being ...
... 2012 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... leading China-based exporter and retailer of high-quality medical dressings ... that it will release financial results for its first ... management will host a conference call to discuss these ...
Cached Medicine Technology:Analysis of the Material Testing Equipment Market 2Winner Medical Group Inc. to Host First Quarter 2012 Earnings Conference Call on Thursday, February 9, 2012 at 08:00 p.m. EST 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: